Key Takeaway
Find out whether Aetna will cover retatrutide once FDA-approved. Coverage expectations, prior authorization tips, and affordable alternatives.
Aetna hasn't yet announced coverage for retatrutide because the medication is still in clinical trials and hasn't received FDA approval. Once retatrutide is approved, coverage will depend on your specific Aetna plan, your BMI, documented weight-related health conditions, and whether prior authorization is required. We outline what to expect and how to prepare below.
What Is Retatrutide and Why Is It Generating Insurance Questions?
Retatrutide is a triple-action receptor agonist targeting GIP, GLP-1, and glucagon receptors . In Phase 2 trials, patients lost an average of 24.2% of their body weight at the highest dose over 48 weeks[1] . These results have driven enormous interest and early questions about insurance coverage.
Retatrutide is currently in Phase 3 trials. No insurer, including Aetna, can finalize coverage decisions until the FDA approves the medication and sets its labeled indications.
How Does Aetna Currently Handle Weight Loss Medications?
Aetna's current approach to GLP-1 weight loss medications gives us clues about how they may handle retatrutide:
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
- Wegovy (semaglutide): Many Aetna plans cover Wegovy with prior authorization for patients with a BMI of 30+ or 27+ with comorbidities, though some employer-sponsored plans exclude it
- Zepbound (tirzepatide): Coverage varies widely by plan. some Aetna plans cover it, others have exclusions for anti-obesity medications
- Prior authorization: Aetna typically requires documentation of BMI, previous weight loss attempts, and related health conditions before approving GLP-1 medications
What Will Determine Whether Aetna Covers Retatrutide?
Several factors will shape Aetna's coverage decision:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- FDA-approved indications: If retatrutide receives a broad weight management label (similar to Wegovy), coverage is more likely
- Clinical trial outcomes: Stronger Phase 3 data typically leads to faster formulary inclusion
- Pricing: The manufacturer's list price will affect where Aetna places retatrutide on their formulary tiers Contact provider for current pricing
- Competitive space: With multiple GLP-1 options available, Aetna may negotiate preferred status for one medication over others
- Employer plan decisions: Even when Aetna covers a medication, individual employer groups can opt out of weight loss drug coverage
How to Prepare for Retatrutide Coverage Through Aetna
You can take steps now to position yourself for the best chance at coverage when retatrutide launches:
- Document your weight history. Keep records of your BMI, previous weight loss attempts, and any weight-related health conditions
- Review your Aetna plan details. Check whether your specific plan covers anti-obesity medications and what the prior authorization requirements are
- Ask your HR department. If you have employer-sponsored Aetna coverage, ask whether the plan includes weight management medications
- Start treatment now. Having a documented history of physician-supervised weight loss treatment strengthens prior authorization requests
What If Aetna Does Not Cover Retatrutide?
If your Aetna plan doesn't cover retatrutide, you have options:
- Compounded alternatives: FormBlends offers compounded semaglutide and compounded tirzepatide at a fraction of brand-name costs
- Appeals process: Your physician can submit a prior authorization appeal with supporting medical documentation
- Plan changes: During open enrollment, you can compare Aetna plan tiers for better weight loss medication coverage
- Manufacturer programs: Drug makers often launch savings cards and patient assistance programs at launch
Medical References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed | ClinicalTrials.gov | DOI]
Do Not Wait for Insurance Approval
Insurance coverage decisions for new medications can take months or even years after FDA approval. FormBlends helps patients access effective weight loss treatment right now through affordable telehealth consultations and compounded medications. Complete your free evaluation today, and our physicians will work with you to find the best treatment for your goals and your budget.